Respibron

Pharmacological properties

Immunological and biological properties

Respibron is an immunomodulator based on a bacterial lysate that increases the bodys resistance to infections due to an increase in the number of serum and secretory antibodies, activation of cellular and humoral factors of non-specific immunity. This leads to a decrease in the frequency of development and severity of respiratory infections, as well as a reduction in the use of antibiotics.

The technology of mechanical disintegration of microbial cultures makes it possible to isolate native highly immunogenic material from large fragments of cell walls of microbial cells by removing ballast antigen-inactive and toxic molecules, which allows inducing a high level of production of specific antibodies. Large antigenic structures are well recognized by the immune system, and the structural immutability of antigenic material, in contrast to the widely used methods of chemical lysis of bacteria, allows the formation of a highly specific response to the most common pathogens of respiratory infections. Respibron has a double mechanism of action:

• activates non-specific resistance (quick protection within 2–4 weeks from the start of taking Resibron) due to the membrane antigens that make up the drug by activating dendritic cells, neutrophils, macrophages and NK cells; induction of phagocytosis and cell lysis by stimulating macrophage adhesion on bacteria;
• activates specific immunity (long-term protection for several years) by increasing the level of production of interleukin (IL-2), specific serum IgA, G, M and sIgA, activation of effector T4 and T8 CD-lymphocytes, B-lymphocytes.

The immunostimulating properties of Resibron are due to:

• in vitro: increased production of IL-12, IL-2, IL-10 and IFNg (CD4 + Th type 1), expression of the receptor for IL-2 in B-lymphocytes, CD4 + and CD8 + into T-lymphocytes, the number of CD4 + and CD8 + effector T -cells;
• in vivo: increased activity of memory IgM B-lymphocytes (CD24 +, CD27 +), expression of the IL-2 receptor in B-lymphocytes and CD4 + and CD8 + in T-lymphocytes; an increase in the level of secretory IgA on the mucous membranes of the respiratory tract, which inhibits the attachment of viral and bacterial cells, neutralizes enzymes and toxins of infectious pathogens, which are especially important in providing Resibron with its prophylactic properties against pathogens of acute, chronic and recurrent infections, as well as diseases of the upper and lower respiratory tract .

Respibron is well absorbed in the mucous membrane of the oral cavity, which makes it convenient to use.

Indications

• Acute, subacute, recurrent and chronic infections of the upper respiratory tract (ARVI, influenza, rhinitis, including allergic, sinusitis, laryngitis, tonsillitis, pharyngitis, nasopharyngitis, tonsillitis, epiglottitis); acute, subacute, recurrent or chronic infections and diseases of the lower respiratory tract, including obstructive (tracheitis, tracheobronchitis, bronchitis, bronchiectasis, hobl).

Thanks to the immunomodulating effect, Resibron reduces the number and intensity of cases of acute respiratory diseases in children who are often ill for a long time, as well as the number of exacerbations of COPD per year and the severity of their course. The drug is used to treat infections that are resistant to antibiotic therapy, as well as complications of bacterial and viral infections. Respibron is allowed to be used in combination with other drugs (antibiotics and mucolytic agents).

Application

For oral use in adults and children over the age of 2 years.

Treatment of acute processes: 1 tablet to dissolve under the tongue for 1-2 minutes 1 time per day (you must refrain from eating for at least 30 minutes). Take daily until symptoms disappear for at least 10 days.The course of treatment involves taking 10 tablets.

Preventive treatment: dissolve 1 tablet under the tongue for 1-2 minutes 1 time per day. The course of treatment is 10 days. After a 20-day break, repeat the 10-day course of taking the drug. The full course of treatment, in which the maximum immunotherapeutic effect is achieved, is 3 months. During the full course of treatment, 30 tablets of Resibron should be taken. That is, Resibron take 3 decade courses for 3 months with two 20-day breaks between them.

Young children are advised to grind the tablet beforehand, moisten it with boiled water at room temperature and put the resulting mixture into the oral cavity.

Contraindications

Hypersensitivity to the drug.

Side effects

Rarely - the occurrence of skin allergic reactions (itching, irritation).

special instructions

During pregnancy and breastfeeding. no toxic effects of respibron on animals were noted, however, it is recommended to avoid the use of the drug during the first 3 months of a confirmed or foreseeable pregnancy.

The ability to influence the reaction rate when driving vehicles and working with other mechanisms. The drug does not affect the ability to drive vehicles and work with other mechanisms.

Interactions

Interactions with other drugs, including antibiotics, were not observed.

Overdose

No cases of overdose have been reported.

Storage conditions

At temperatures up to 25 ° C.